Medical Oncologist
Lung cancer mutations
MET Exon 14 Skipping and MET Amplification — Treatment Explained
A MET exon 14 skipping result means your tumour has a targetable driver mutation. A specific class of tablets — MET inhibitors — is the recommended treatment for advanced non-small cell lung cancer with this finding.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- A driver mutation — MET exon 14 skipping keeps the MET protein permanently switched on, telling cancer cells to keep dividing.
- Targeted tablet treatment — MET inhibitors are taken as daily tablets and work differently from chemotherapy — they block the specific signal driving this cancer.
- Testing method matters — RNA-based sequencing is preferred for detecting this mutation. DNA-only tests can miss it.
- MET amplification is different — Your report may show MET amplification instead of exon 14 skipping. They are separate findings with different clinical meanings.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
MET exon 14 skipping is a driver mutation found mainly in non-small cell lung cancer. It is treated with a class of drugs called MET tyrosine kinase inhibitors — taken as tablets. Two agents, capmatinib and tepotinib, are approved by the FDA for this specific mutation.
What is MET exon 14 skipping?
MET is a gene that helps cells grow and divide. A section of this gene called exon 14 normally acts as a brake — it signals the MET protein to switch off when it is no longer needed.
When exon 14 is skipped or deleted, that brake disappears. The MET protein stays permanently switched on, telling cancer cells to keep dividing. This is what makes it a driver mutation — it is actively driving the cancer's growth.
Because the mutation is the engine driving the cancer, blocking it directly with a targeted drug can work better than chemotherapy alone. This is why confirming the mutation is the first step before your oncologist recommends a treatment.
How is MET amplification different from exon 14 skipping?
MET amplification means your tumour cells carry too many copies of the MET gene. Exon 14 skipping means the structure of the gene itself is abnormal. They are different findings, and your report will state which one applies to you.
MET amplification can occur as a primary driver — the main cause of the cancer's growth — or as a secondary change that develops after a different targeted therapy stops working. The clinical meaning and treatment options differ between the two.
If your report shows MET amplification and you are unsure whether it is a primary or secondary finding, that question matters. Ask your oncologist to explain what the finding means in the context of your treatment history.
How is MET exon 14 skipping treated?
MET inhibitors are the drug class used for MET exon 14 skipping. They are taken as daily tablets. NCCN and ASCO guidance recommends them as the preferred first-line treatment for advanced non-small cell lung cancer with confirmed exon 14 skipping.
Two agents are most widely approved for this mutation: capmatinib and tepotinib. Both block the overactive MET protein. Your oncologist will advise which agent is available and appropriate in your situation.
MET inhibitors have a different side-effect profile from chemotherapy. Fluid retention — swelling in the legs or ankles — is among the most commonly reported effects. Nausea and changes in blood test results, including liver and kidney markers, are also seen and monitored with regular blood tests.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
Before your next appointment, confirm these
- Check whether your NGS report used RNA-based or DNA-only sequencing — RNA-based is preferred for detecting exon 14 skipping.
- Confirm whether the test checked specifically for MET exon 14 skipping, not only for MET amplification.
- If MET exon 14 skipping is confirmed, ask whether a MET inhibitor tablet is the recommended first treatment for your stage.
- Bring a printed or digital copy of your biomarker report to the appointment.
- If your tissue sample was small, ask whether a liquid biopsy (blood test) can be used for further testing.
- List all medicines, supplements, and traditional preparations you are taking — some interact with MET inhibitor tablets.
Words you will see in your report
- MET gene
- A gene that controls how cells grow. Mutations in MET can drive cancer to grow without stopping.
- MET exon 14 skipping
- A mutation where a regulatory section of the MET gene is deleted, leaving the MET protein permanently active and driving tumour growth.
- MET amplification
- Too many copies of the MET gene in tumour cells, producing excess MET protein. A separate finding from exon 14 skipping, with a different clinical meaning.
- MET inhibitor
- The drug class that blocks the overactive MET protein. Taken as a daily tablet, not by infusion.
- Capmatinib
- A MET inhibitor tablet approved by the FDA for non-small cell lung cancer with MET exon 14 skipping.
- Tepotinib
- A MET inhibitor tablet approved by the FDA and EMA for non-small cell lung cancer with MET exon 14 skipping.
- NGS (next-generation sequencing)
- The laboratory test that reads large sections of the tumour's genetic code to identify mutations including MET exon 14 skipping.
- RNA-based sequencing
- A sequencing method that reads gene instructions at the RNA stage. Preferred for detecting exon 14 skipping because DNA sequencing can miss it.
- Liquid biopsy
- A blood test that detects tumour DNA circulating in the bloodstream. Can pick up MET exon 14 skipping in some patients when tissue is limited.
Questions about MET mutations that need a longer answer
Can MET exon 14 skipping be treated at any stage of lung cancer?
It is most established in advanced or metastatic non-small cell lung cancer, which is the setting where most clinical evidence has been gathered and where NCCN and ASCO guidance recommends MET inhibitor therapy as a first-line option for confirmed exon 14 skipping. Whether a MET inhibitor is appropriate at an earlier stage depends on your specific situation, including the full staging, other biomarker results, and your fitness. Bring this question to your oncologist with your complete report in hand.
Is MET exon 14 skipping an inherited mutation?
No. MET exon 14 skipping is a somatic mutation — it develops in the tumour cells during the person's lifetime and is not passed down from parents or passed on to children. Your family members do not need to be tested for this specific finding. Somatic mutations are different from hereditary cancer risk variants such as BRCA1 or BRCA2. If your family has a pattern of cancers across generations, that is a separate question about hereditary risk, and a genetic counsellor can advise whether a different type of test is appropriate.
What happens if a MET inhibitor stops working?
Resistance can develop in a proportion of patients over time, usually because the tumour acquires a new genetic change that bypasses the drug. When this happens, a repeat biopsy or liquid biopsy is often recommended to identify what has changed. Options after resistance include a different MET inhibitor where available, combination regimens being studied in clinical trials, or other systemic treatments depending on what the new testing shows. Resistance does not end all options — it means the next plan needs to be built on what the tumour looks like now.
Does this mutation affect whether I can also have immunotherapy?
The relationship between MET exon 14 skipping and immunotherapy response is an area of active research. Some evidence suggests that tumours with this mutation may respond less predictably to checkpoint inhibitors, but the picture is not fully established. NCCN guidance recommends checking PD-L1 and other relevant markers alongside MET testing, because some patients may be candidates for immunotherapy in addition to or instead of a MET inhibitor, depending on the full result profile. Discuss your complete biomarker results with your oncologist rather than drawing conclusions from any single marker.
Can I take MET inhibitor tablets alongside other medicines?
MET inhibitors are processed by the liver, and some commonly taken medicines — including certain blood pressure drugs, antifungals, and herbal supplements — can affect how much of the drug reaches your bloodstream. This does not mean you have to stop other medicines, but it does mean your oncologist and pharmacist need a complete list of everything you are taking, including over-the-counter products and traditional preparations. Do not stop any medicine without asking your team first. Dose adjustments can sometimes manage an interaction without stopping either drug.
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
What does it mean if my report says MET exon 14 skipping?
It means your tumour has a specific genetic change that can be targeted with a class of drugs called MET inhibitors. NCCN guidance lists MET inhibitor therapy as the preferred approach for advanced non-small cell lung cancer with confirmed MET exon 14 skipping, which changes the treatment recommendation away from chemotherapy as the first option. Ask your oncologist to walk you through the report and explain which treatment applies to your stage and situation.
Which drugs are approved for MET exon 14 skipping?
Two MET inhibitor tablets are most widely approved for this mutation: capmatinib and tepotinib, both approved by the FDA for non-small cell lung cancer with MET exon 14 skipping. Tepotinib also has EMA approval. Savolitinib has regulatory approval in some countries. At CION centres, your oncologist will review your biomarker results and discuss which option is appropriate and accessible in your situation.
Do I need a new biopsy to test for MET exon 14 skipping?
Usually not — the sample from your existing biopsy can be used, provided enough material was preserved. However, if your original test used DNA-only sequencing, your oncologist may recommend re-testing with RNA-based sequencing, which is more sensitive for detecting exon 14 skipping. A liquid biopsy (blood test) can also detect this mutation in some patients when tissue is limited. Ask your oncologist whether your existing sample is sufficient or whether additional testing is needed.
Is MET exon 14 skipping the same as MET amplification?
No. They are two different findings. MET exon 14 skipping is a structural change in how the MET gene is read. MET amplification means too many copies of the gene are present in the tumour. Both involve the MET protein but have different clinical meanings, and the treatment eligibility criteria differ. Your report should specify which one applies to you. If the wording is unclear, ask your oncologist to explain the exact finding and what it means for your options.
What can I realistically expect from a MET inhibitor?
MET inhibitors aim to control the cancer by blocking the signal driving its growth — to shrink tumours or keep the disease stable. Response rates in clinical trials reviewed by NCCN and ASCO show that a meaningful proportion of patients with MET exon 14 skipping achieve tumour shrinkage. No oncologist can predict a specific outcome for any individual. The goal is to control the disease as effectively and for as long as possible, and your oncologist can explain what a response would look like in your specific case.
What side effects do MET inhibitors cause?
MET inhibitors have a different side-effect profile from chemotherapy. Fluid retention — swelling in the legs or ankles — is one of the most commonly reported effects. Nausea and changes in blood test results, including liver and kidney markers, are also seen. Hair loss and severe immune suppression, which are common with chemotherapy, are not typical. Your oncologist will monitor your blood tests regularly and can adjust the dose or manage side effects if they occur. Report any new swelling, shortness of breath, or significant nausea to your team promptly.